Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Processing Request
Estimands and estimators of two-level methods using return to baseline strategy for longitudinal clinical trials with incomplete daily patient reported outcomes.
Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Processing Request
- المؤلفون: Jin M;Jin M; Liu G; Liu G
- المصدر:
Journal of biopharmaceutical statistics [J Biopharm Stat] 2023 Jul 04; Vol. 33 (4), pp. 425-438. Date of Electronic Publication: 2021 Jun 24.
- نوع النشر :
Journal Article
- اللغة:
English
- معلومة اضافية
- المصدر:
Publisher: Taylor & Francis Country of Publication: England NLM ID: 9200436 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-5711 (Electronic) Linking ISSN: 10543406 NLM ISO Abbreviation: J Biopharm Stat Subsets: MEDLINE
- بيانات النشر:
Publication: 2005- : Abingdon, Oxford : Taylor & Francis
Original Publication: New York, N.Y. : Marcel Dekker, c1991-
- الموضوع:
- نبذة مختصرة :
Returning to baseline (RTB) has been a practical method for handling missing data. Here we consider longitudinal clinical trials with daily patient reported outcomes (PROs), where efficacy endpoints are often defined as the average daily values in a cycle (such as a month or a week). The conventional method treats data at cycle level and ignores daily values. In this paper, we build a two-level constrained longitudinal data analysis (cLDA) model on daily values and propose two-level RTB method to impute daily values. Standard multiple imputation (MI) approach and likelihood-based approach are proposed and evaluated by simulations.
- Contributed Indexing:
Keywords: Missing not at random; multiple imputations; reference-based imputation; return to baseline
- الموضوع:
Date Created: 20210624 Date Completed: 20230626 Latest Revision: 20230626
- الموضوع:
20230626
- الرقم المعرف:
10.1080/10543406.2021.1934855
- الرقم المعرف:
34162312
No Comments.